GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » 908 Devices Inc (NAS:MASS) » Definitions » ROC (Joel Greenblatt) %

908 Devices (908 Devices) ROC (Joel Greenblatt) % : -240.56% (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is 908 Devices ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. 908 Devices's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -240.56%.

The historical rank and industry rank for 908 Devices's ROC (Joel Greenblatt) % or its related term are showing as below:

MASS' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -216.49   Med: -117.61   Max: -47.35
Current: -188.09

During the past 6 years, 908 Devices's highest ROC (Joel Greenblatt) % was -47.35%. The lowest was -216.49%. And the median was -117.61%.

MASS's ROC (Joel Greenblatt) % is ranked worse than
75.53% of 850 companies
in the Medical Devices & Instruments industry
Industry Median: -0.61 vs MASS: -188.09

908 Devices's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was -33.20% per year.


908 Devices ROC (Joel Greenblatt) % Historical Data

The historical data trend for 908 Devices's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

908 Devices ROC (Joel Greenblatt) % Chart

908 Devices Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial -85.57 -99.03 -136.18 -173.24 -216.49

908 Devices Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -259.90 -185.90 -176.38 -155.45 -240.56

Competitive Comparison of 908 Devices's ROC (Joel Greenblatt) %

For the Medical Devices subindustry, 908 Devices's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


908 Devices's ROC (Joel Greenblatt) % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, 908 Devices's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where 908 Devices's ROC (Joel Greenblatt) % falls into.



908 Devices ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(8.989 + 14.938 + 4.181) - (3.91 + 10.629 + 5.994)
=7.575

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(7.486 + 16.356 + 3.831) - (3.582 + 10.483 + 3.189)
=10.419

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of 908 Devices for the quarter that ended in Mar. 2024 can be restated as:

ROC (Joel Greenblatt) %(Q: Mar. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Mar. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-43.948/( ( (9.575 + max(7.575, 0)) + (8.969 + max(10.419, 0)) )/ 2 )
=-43.948/( ( 17.15 + 19.388 )/ 2 )
=-43.948/18.269
=-240.56 %

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


908 Devices  (NAS:MASS) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


908 Devices ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of 908 Devices's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


908 Devices (908 Devices) Business Description

Traded in Other Exchanges
N/A
Address
645 Summer Street, Boston, MA, USA, 02210
908 Devices Inc manufactures medical devices. It has developed an innovative suite of purpose-built handheld and desktop mass spectrometry, or Mass Spec, devices for the point-of-need. Mass Spec devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers to directly address some of the most critical problems in life sciences research, bioprocessing, industrial biotech, forensics, and adjacent markets.
Executives
Griffith Joseph H. Iv officer: Chief Financial Officer 68 ELM STREET, HOPKINTON MA 01748
Christopher D. Brown officer: Chief Technology Officer C/O 908 DEVICES INC., 645 SUMMER STREET, BOSTON MA 02210
Kevin J. Knopp director, officer: President and CEO C/O 908 DEVICES INC., 645 SUMMER STREET, BOSTON MA 02210
Michael S. Turner officer: VP, General Counsel C/O 908 DEVICES INC., 645 SUMMER STREET, BOSTON MA 02210
Maura Fitzpatrick officer: VP, Product Management & Mktg 908 DEVICES INC., 645 SUMMER STREET, BOSTON MA 02210
Mark Spoto director C/O 908 DEVICES INC., 645 SUMMER STREET, BOSTON MA 02210
Michele Fournier officer: Chief People Officer 908 DEVICES INC., 645 SUMMER STREET, BOSTON MA 02210
Trent A. Basarsky officer: Vice President, Commercial C/O PROTEINSIMPLE, 3040 OAKMEAD VILLAGE DRIVE, SANTA CLARA CA 95051
John Kenneweg officer: Vice President, Government C/O 908 DEVICES INC., 645 SUMMER STREET, BOSTON MA 02210
Anthony Hunt director 41 SEYON STREET, BUILDING 1, SUITE 100, WALTHAM MA 02452
Nicolas Barthelemy director 1750 BELLA LAGUNA CT, ENCINITAS CA 92024
Marcia Eisenberg director C/O 908 DEVICES INC., 645 SUMMER STREET, BOSTON MA 02210
Jeffrey P. George director C/O AMNEAL PHARMACEUTICALS, INC., 400 CROSSING BOULEVARD, BRIDGEWATER NJ 08807
Fenel M Eloi director C/O INTERLEUKIN GENETICS INC, 135 BEAVER STREET, WALTHAM MA 02452
Keith Crandell director, 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631